Sangamo Therapeutics (LTS:0R1D) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R1D Sangamo Therapeutics Inc LTS:0R1D
27 GF Score
Price $0.16
GF Value $0.19
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Sangamo Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Sangamo Therapeutics Quality Rank Related Terms

LTS:0R1D
27GF Score
Sangamo Therapeutics Inc LTS:0R1D
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sangamo Therapeutics (LTS:0R1D) Overvalued in 2026?

Based on GuruFocus' analysis, Sangamo Therapeutics stock appears to be undervalued. The current stock price of $0.16 is trading 14.2% below its estimated GF Value™ of $0.19. GuruFocus considers Sangamo Therapeutics to be Modestly Undervalued.

Key valuation signals for LTS:0R1D:

  • Quality Rank:
  • GF Value™: $0.19 vs. price of $0.16 (14.2% below fair value)
  • GF Score™: 27/100 with 6 warning signs

No single metric tells the full story. See the LTS:0R1D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sangamo Therapeutics Business Description

Other Exchanges SGMO:USAGBY:Germany
Address 501 Canal Boulevard, Richmond, CA, USA, 94804
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
27GF Score

Get the complete analysis for LTS:0R1D

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price
$0.19
GF Value